Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 29Carcinoma, Hepatocellular 16Prostatic Neoplasms 12Neoplasm Metastasis 11Carcinoma, Non-Small-Cell Lung 9Neoplasms 8Sarcoma 7Osteosarcoma 6Neuroendocrine Tumors 6Brain Neoplasms 6Urinary Bladder Neoplasms 5Kidney Neoplasms 5Carcinoma, Transitional Cell 5Breast Neoplasms 5Sarcoma, Ewing 4Melanoma 4Lung Neoplasms 4Recurrence 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Clear-cell metastatic renal cell carcinoma 3Carcinoid Tumor 3Adrenocortical Carcinoma 3Adenocarcinoma 3Wilms Tumor 2Uterine Cervical Neoplasms 2Urethral Neoplasms 2Thyroid Neoplasms 2Thyroid Diseases 2Thyroid Cancer, Papillary 2

Interventions

trebananib 1pembrolizumab 1cabozantinib 1Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Hepatocellular Carcinoma × cabozantinib × Clear all
NCT04442581 2023-04-05

Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer

University of Washington

Phase 2 Terminated
2 enrolled 12 charts
Gastrointestinal

Advanced Hepatocellular Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡